BeOne Medicines Posts Strong 2025 Growth on BRUKINSA Momentum
Event summary
- BeOne Medicines reported $5.3B in full-year 2025 revenue, up 40% YoY, driven by BRUKINSA sales growth of 49%
- BRUKINSA generated $3.9B in global sales for 2025, with U.S. sales reaching $2.8B
- TEVIMBRA sales grew 19% YoY to $737M, while Amgen-licensed products increased 33% to $486M
- GAAP net income turned positive at $287M for 2025 after a $645M loss in 2024
The big picture
BeOne Medicines' strong 2025 performance underscores its growing dominance in oncology, particularly through BRUKINSA's global expansion. The company's ability to convert clinical success into commercial wins positions it favorably against competitors like AbbVie and Johnson & Johnson. However, sustaining this momentum will require navigating regulatory hurdles and maintaining operational efficiency amid increasing R&D investments.
What we're watching
- Product Pipeline Execution
- The pace at which BeOne advances its late-stage hematology assets and solid tumor portfolio will determine its ability to sustain growth momentum.
- Regulatory Approvals
- Key regulatory decisions in 2026, particularly for Sonrotoclax in the U.S. and Europe, could expand BeOne's market reach and revenue streams.
- Market Competition
- Whether BRUKINSA can maintain its leadership position in the BTK inhibitor class amid potential new entrants and therapeutic alternatives.
Related topics